T. Lin

Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.

A. Tolcher, Toshio Shimizu, K. Papadopoulos, 2010 .

Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease

Y. Ko, C. Suh, S. Lim, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies.

J. Byrd, I. Flinn, J. Brown, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).

A. Tolcher, M. Kies, G. Blumenschein, 2010 .

Porcine bocaviruses: genetic analysis and prevalence in Chinese swine population

S. Yuan, J. Long, A. Cheung, 2011, Epidemiology and Infection.

Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines.

K. Ang, B. Goh, Y. Guo, 2013, Oral oncology.

A machine learning-based approach to predicting the malignant and metastasis of thyroid cancer

J. Fei, Sibo Zhu, Wen-juan Xu, 2022, Frontiers in Oncology.

Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer.

G. Folprecht, D. Strumberg, U. Hacker, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX or FOLFIRI in combination with sequentially administered regorafenib as first- or second-line treatment in patients with colorectal cancer

C. Köhne, G. Folprecht, D. Strumberg, 2011 .

Regulation of expression of cd133, a colon cancer stem cell marker and other stemness genes/pathways, by celecoxib: Clues from clinical observations.

C. Ulrich, E. Lin, W. Grady, 2016, Journal of Clinical Oncology.